Korean J Intern Med.
2018 Mar;33(2):383-390. 10.3904/kjim.2015.162.
Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee
- Affiliations
-
- 1Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 2Department of Internal Medicine, Dong-A University Hospital, Busan, Korea. drosy@dau.ac.kr
- 3Department of Internal Medicine, Pusan National University Hospital, Busan, Korea.
- 4Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea.
- 5Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea.
- 6Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.
- 7Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea.
- 8Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
- 9Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea.
- 10Department of Internal Medicine, Konyang University Hospital, Daejeon, Korea.
- 11Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- KMID: 2411550
- DOI: http://doi.org/10.3904/kjim.2015.162
Abstract
- BACKGROUND/AIMS
Because of rarity, role of chemotherapy of bladder adenocarcinoma are still unidentified. Therefore, we performed a retrospective analysis of the clinical features and chemotherapy outcomes of bladder adenocarcinoma.
METHODS
Eligible patients for this retrospective analysis were initially diagnosed with bladder adenocarcinoma and presented with a clinically no other primary site of origin. The collected data included age, gender, performance status, stage, hemoglobin, albumin, initial date of diagnosis, treatment modality utilized, response to treatment, presence of relapse, last status of patient, and last date of follow-up.
RESULTS
We retrospectively reviewed 29 patients, who were treated with chemotherapy for bladder adenocarcinoma at 10 Korean medical institutions from 2004 to 2014. The median age of patients was 58 years (range, 17 to 78) and 51.7% of the patients were female. Urachal adenocarcinoma was identified in 15 patients. Of 27 symptomatic patients, 22 experienced gross hematuria. Twelve patients were treated with 5-f luorouracil based chemotherapy, five were gemcitabine based, three were taxane and others. Thirteen of them achieved complete response (10.3%) or partial response (34.5%). Median progression-free survival (PFS) and overall survival (OS) for all patients were 10.6 months (95% confidence interval [CI], 9.5 to 11.6) and 24.5 months (95% CI, 1.2 to 47.8), respectively. The cases of urachal adenocarcinoma exhibited worse tendency in PFS and OS (p = 0.024 and p = 0.046, respectively).
CONCLUSIONS
Even though bladder adenocarcinoma had been observed moderate effectiveness to chemotherapy, bladder adenocarcinoma is a highly aggressive form of bladder cancer. PFS and OS were short especially in urachal carcinoma.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Adjuvant M-VAC Chemotherapy in Locally Advanced Bladder Cancer
- A case of metastatic adenocarcinoma of bladder from stomach cancer
- Primary Adenocarcinoma of the Bladder Treated by Pelvic Exenteration : Report of A Case
- A case of metastatic adenocarcinoma at uterine myoma from gastric cancer
- Chemotherapy for Patients with Colorectal Cancer - When and How?
